Apogee Therapeutics, Inc. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated statement of cash flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023
Cash flows from operating activities:
Net loss
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Depreciation expense
Equity-based compensation expense
Amortization of discounts on marketable securities
Non-cash lease expense
Changes in operating assets and liabilities:
Prepaid expenses and other current assets
Other assets
Accounts payable
Operating lease liability
Accrued expenses
Net cash used in operating activities
Cash flows from investing activities:
Purchases of marketable securities
Maturities of marketable securities
Purchases of property and equipment
Net cash used in investing activities
Cash flows from financing activities:
Proceeds from issuance of common stock and pre-funded warrants, net of issuance costs
Proceeds from issuance of common stock under ATM equity offering program, net of issuance costs
Proceeds from exercise of options and employee stock purchase plan purchases
Net cash provided by financing activities
(Decrease) increase in cash, cash equivalents and restricted cash
Cash, cash equivalents and restricted cash, beginning of period
Cash, cash equivalents and restricted cash, end of period
Supplemental disclosures of non-cash activities:
Exchange of 72,636,636 preferred, common, and incentive units in connection with the Reorganization (Note 1)
Operating lease right-of-use asset obtained in exchange for operating lease liability
Deferred financing issuance costs in accounts payable and accrued expenses
Purchases of property and equipment included in accounts payable and accrued expenses
Reconciliation of cash, cash equivalents and restricted cash:
Cash and cash equivalents
Restricted cash

Comments